This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MAP3K4 / Mitogen-activated protein kinase kinase kinase 4 · IHC design guide
Design Immunohistochemistry for MAP3K4
Plan MAP3K4 paraffin IHC using the catalog antibody's 1:100–1:300 dilution (datasheet: A04842). Assess nuclear and cytoplasmic staining against tissue controls, bearing in mind that HPA rates its tissue staining evidence uncertain (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MAP3K4 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear and cytoplasmic staining (HPA tissue IHC) | |
| Staining pattern | General nuclear and cytoplasmic staining (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Skeletal muscle |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep paraffin-section fixation consistent. (standard IHC practice; not target-specific) | |
| Caveat | Skeletal myocytes show no staining despite reported high expression (HPA tissue IHC; UniProt) | |
| Regulation | Staining intensity varies by tissue and cell type (HPA tissue IHC) | |
| Isoform / epitope | 2 isoforms; epitope differences are unspecified (UniProt) |
Section 1
Recommended MAP3K4 IHC & IF Protocols
The catalog antibody protocol is paired with a published MAP3K4 liver IHC method covering blocking and HRP/DAB detection (PMC9664664).
| Sample | Paraffin-embedded human heart tissue; fixative not specified (datasheet A04842) |
| Fixation | Image fixative and duration unreported (datasheet A04842); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-MAP3K4, 1:100 - 1:300 (datasheet A04842) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MAP3K4-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General nuclear and cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteTry citrate pH 6.0 HIER at 95–98 °C for 20 min first (page antigen retrieval); the liver article does not specify retrieval (PMC9664664).
Section 2
What Is the Expected MAP3K4 Staining Pattern?
MAP3K4 is a cytoplasmic protein with reported perinuclear, vesicular-like localization and no transmembrane segment (UniProt Q9Y6R4). In paraffin-section IHC, assess staining in the cell populations HPA reports as positive, including adrenal glandular, bronchial epithelial, and bone-marrow hematopoietic cells (HPA tissue IHC). HPA describes general nuclear and cytoplasmic staining, but rates its tissue IHC evidence Uncertain; its ICC-IF cytosolic localization is Approved (HPA tissue IHC; HPA subcellular).
| Cytoplasmic staining in adrenal glandular, bronchial epithelial, or bone-marrow hematopoietic cells (HPA: High in each population). | This fits the reported IHC distribution and UniProt cytoplasmic localization (HPA tissue IHC; UniProt Q9Y6R4). Compare signal with neighboring cells and controls; HPA rates the IHC pattern Uncertain (HPA tissue IHC). |
| Nuclear-only staining, or staining confined to another unexpected compartment. | Question specificity and review controls. UniProt places MAP3K4 in the cytoplasm, while HPA describes both nuclear and cytoplasmic tissue staining with Uncertain reliability (UniProt Q9Y6R4; HPA tissue IHC). Nuclear signal alone is therefore inconclusive. |
| Strong staining in a cell population absent from the selected tissue's reported HPA pattern. | Possible explanations include cross-reactivity or endogenous detection activity; these are general IHC possibilities, not established MAP3K4 effects. Check the tissue-specific HPA cell annotation and detection controls before assigning the signal to MAP3K4 (HPA tissue IHC). |
| Diffuse color across cells and surrounding tissue, with little cellular definition. | Treat this as background until controls show otherwise. Review blocking, washing, antibody concentration, and chromogen development as general IHC variables. A broad haze cannot establish the cytoplasmic pattern reported by UniProt or the cell-resolved patterns reported by HPA (UniProt Q9Y6R4; HPA tissue IHC). |
| No signal in adrenal glandular or bronchial epithelial cells (HPA: High in each population). | Check tissue preservation, retrieval, detection, and control performance using standard IHC practice before concluding that MAP3K4 is absent. HPA's High designation is an observed pattern, not a guarantee for every section or antibody (HPA tissue IHC). |
💡Expected MAP3K4 appearanceA credible positive result shows cell-defined cytoplasmic staining in an HPA High population, such as adrenal glandular cells; isolated nuclear color or diffuse background calls for control review, given HPA's Uncertain IHC reliability (UniProt Q9Y6R4; HPA tissue IHC).
| Compartment evidence | UniProt reports cytoplasmic and perinuclear, vesicular-like MAP3K4; HPA ICC-IF approves cytosol, whereas HPA tissue IHC describes nuclear and cytoplasmic staining with Uncertain reliability (UniProt Q9Y6R4; HPA subcellular; HPA tissue IHC). |
| Choice of tissue and cell population | HPA reports High staining in several specific populations, but no staining in skeletal myocytes (HPA tissue IHC). Choose and score the annotated cells; whole-tissue intensity can obscure their pattern. |
| Skeletal-muscle evidence conflict | UniProt reports high tissue expression in skeletal muscle, while HPA IHC reports myocytes as Not detected (UniProt Q9Y6R4; HPA tissue IHC). Do not use those myocytes as an assured positive IHC control. |
| Antibody validation | HPA lists HPA007625 as IHC Uncertain and ICC Approved (HPA antibodies). Its ICC status supports its cell-imaging use but does not upgrade the reliability of tissue IHC. |
| Isoforms and epitope information | UniProt lists two isoforms and a protein kinase domain at residues 1343–1601 (UniProt Q9Y6R4). No antibody epitope is supplied, so neither isoform recognition nor an epitope-specific retrieval effect can be inferred. |
| Processing and target-specific fixation evidence | UniProt lists one chain spanning residues 1–1608, with no signal peptide or propeptide (UniProt Q9Y6R4). The supplied sources do not report MAP3K4-specific fixation sensitivity or justify a processing-based staining prediction. |
| Situation | Likely cause | Next action |
|---|---|---|
| High-population cells are blank (HPA: High in adrenal glandular cells). | The staining run may have failed, or the chosen section may not reproduce HPA's Uncertain pattern (HPA tissue IHC). | Confirm the annotated cells are present, inspect a concurrent positive control, then optimize retrieval and detection using standard IHC practice. |
| Signal is predominantly nuclear. | HPA reports nuclear and cytoplasmic tissue staining, but labels that evidence Uncertain; UniProt reports cytoplasmic localization (HPA tissue IHC; UniProt Q9Y6R4). | Review background and controls, then describe the observed compartment explicitly. Avoid calling nuclear-only staining definitive MAP3K4 localization. |
| Color appears in unexpected cells or persists without primary antibody. | Cross-reactivity is possible; persistence without primary antibody suggests endogenous detection activity or nonspecific reagent binding (general IHC practice). | Compare with a no-primary control and the tissue's HPA cell annotation; adjust the relevant blocking or detection step before scoring. |
| The section has diffuse, poorly resolved color. | Excess antibody, incomplete washing, or overdevelopment can produce background (general IHC practice). | Titrate the primary antibody and detection development, improve washes, and accept a result only when individual stained cells remain distinguishable. |
| Skeletal myocytes are blank despite a planned positive-control role. | HPA reports skeletal myocytes as Not detected, despite UniProt's high skeletal-muscle tissue expression (HPA tissue IHC; UniProt Q9Y6R4). | Use an HPA High cell population as the IHC comparison and record the source discrepancy; do not classify this blank result alone as assay failure. |
| ICC-IF appears cytosolic, but tissue IHC gives a broader pattern. | HPA approves cytosolic ICC-IF localization while rating its nuclear and cytoplasmic tissue IHC pattern Uncertain (HPA subcellular; HPA tissue IHC). | Evaluate the paraffin section with its own controls and cell annotations. Use ICC-IF as localization context, without treating its approval as tissue-IHC validation. |
Experiment evidence
IHC & IF images showing MAP3K4 staining
A04842 · IHCImmunohistochemistry analysis of paraffin-embedded human heart tissue, using MAP3K4 Antibody. The picture on the right is blocked with the s
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000085511-MAP3K4/tissue/cerebral+cortex#imid_3138240
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000085511-MAP3K4/tissue/colon#imid_3138174
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000085511-MAP3K4/tissue/liver#imid_3138167
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000085511-MAP3K4/tissue/pancreas#imid_3138126
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA007625; green = MAP3K4, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA007625; green = MAP3K4, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MAP3K4 IHC & IF
🧪Run adrenal gland first; glandular cells should stain (HPA: High in adrenal gland glandular cells). Use skeletal muscle as the negative tissue (HPA: Not detected in skeletal muscle myocytes); on the adrenal slide, assess any adjacent nonglandular cells for absence of specific staining without assuming they are MAP3K4-negative.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Skeletal muscle (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MAP3K4 in A-431, U-251MG, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and clonality (standard IHC practice). Use a knockout specimen or peptide block as a biological specificity control; peptide blocking is shown for the catalog antibody in human heart paraffin sections (A04842 tissue-IHC caption). Quench endogenous peroxidase and inspect background on the adrenal slide (standard chromogenic IHC practice).
⚠️Feasibility: A target-specific fixation window and retrieval dependency are unreported in the supplied evidence; optimize retrieval empirically for paraffin sections. The selected caption shows staining in paraffin-embedded heart tissue but does not state the fixative (A04842 tissue-IHC caption), and the evidence does not establish whether frozen sections or IF are easier. Skeletal muscle needs cautious interpretation as a negative control because HPA reports myocytes as not detected while UniProt reports high tissue expression (HPA: Not detected in skeletal muscle myocytes; UniProt: tissue specificity).
HPA tissue IHC evidence for MAP3K4
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Lymphoid tissue | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Caudate | Glial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skeletal muscle | Myocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced MAP3K4 IHC Tips
Troubleshoot MAP3K4 staining in paraffin sections by checking retrieval, compartment, controls and cell-specific signal before comparing chromogenic scores.
How should I retrieve MAP3K4 antigen in paraffin sections when staining is weak?
Start with citrate buffer at pH 6.0 for heat-induced retrieval at 95–98 °C for 20 min (page retrieval setting). Allow sections to cool in buffer, then compare staining with a matched section processed without retrieval to assess retrieval-dependent background (general IHC practice). Keep antibody dilution, detection and development time identical across sections so a change in signal can be attributed to retrieval (general IHC practice). If staining remains weak, test a second retrieval condition on parallel sections while checking tissue preservation and background (general IHC practice). The selected tissue image establishes staining in paraffin-embedded heart, but its caption does not report a retrieval method (A04842 caption).
Could fixation explain weak or uneven MAP3K4 staining in my sections?
MAP3K4-specific sensitivity to fixation is unknown from the supplied evidence; the selected image identifies paraffin-embedded human heart but does not state its fixative (A04842 caption). Record fixative, fixation duration and processing history for each specimen, then compare sections processed together using the same retrieval and detection steps (general IHC practice). For a controlled comparison, vary one preparation condition at a time and include a section from the same block in each staining run (general IHC practice). Examine morphology and staining across the section before attributing weak signal to fixation, since uneven processing or section loss can also impair interpretation (general IHC practice). Neither tissue expression patterns nor MAP3K4 sequence features establish a fixation effect (HPA: tissue profile; UniProt Q9Y6R4: topology and modifications).
Which staining compartments should I expect for MAP3K4 in tissue?
Assess cytoplasmic staining first: MAP3K4 is reported in the cytoplasm and perinuclear region, including vesicular-like structures described as probably Golgi-associated (UniProt Q9Y6R4: subcellular location). An independent cell imaging record places it in the cytosol (HPA: approved cytosol location). Tissue IHC also reports general nuclear and cytoplasmic staining, although its reliability is rated uncertain (HPA: tissue profile and reliability). Record nuclear and cytoplasmic signal separately rather than merging them into one score, and compare each compartment with the negative control (general IHC practice). Predominantly nuclear staining warrants extra scrutiny because it differs from the approved cytosolic cell imaging location (HPA: approved cytosol location).
How should isoforms and epitope placement affect my MAP3K4 IHC interpretation?
MAP3K4 has 2 annotated isoforms, so determine whether the antibody’s documented immunogen is shared before interpreting staining as total MAP3K4 (UniProt Q9Y6R4: isoforms; general IHC practice). Its protein kinase domain spans residues 1343–1601, while documented phosphorylation sites include residues 84, 431 and 447 (UniProt Q9Y6R4: domains and modified residues). The supplied evidence does not map this antibody’s epitope, so it cannot establish isoform coverage or phosphorylation sensitivity (A04842 caption; UniProt Q9Y6R4: isoforms and modifications). Compare staining with the selected image’s peptide-blocked control when available, while remembering that peptide competition alone does not establish which isoform contributes signal (A04842 caption; general IHC practice).
How can I cross-check MAP3K4 localisation by multiplex immunofluorescence?
For a separate IF assay, pair MAP3K4 with a validated marker for the cell type being examined, and verify that each primary and secondary combination remains distinct in single-label controls (general IF practice). Choose a fluorophore whose emission is separated from measured tissue autofluorescence, and include an unstained section to identify that background (general IF practice). Because MAP3K4 lacks a transmembrane segment and has a cytoplasmic or cytosolic location, use a controlled permeabilisation step when staining fixed cells or sections for an intracellular epitope (UniProt Q9Y6R4: topology and location; HPA: approved cytosol location). Titrate permeabilisation alongside a no-primary control; excessive extraction can obscure cytoplasmic distribution (general IF practice). The paraffin tissue caption supplies no IF fixation or permeabilisation conditions (A04842 caption).
How do I reduce diffuse chromogenic background without losing MAP3K4 signal?
Run a no-primary control through the same chromogenic detection steps to identify signal from the detection system or tissue itself (general IHC practice). If using peroxidase detection, block endogenous peroxidase before applying the primary antibody, then inspect the control before adjusting MAP3K4 staining (general IHC practice). Titrate primary antibody concentration and incubation time on matched sections, and use the same wash schedule and DAB development time for each comparison (general IHC practice). Check whether diffuse stain follows tissue folds, drying edges or damaged areas, since those patterns complicate cellular scoring (general IHC practice). Interpret any residual cytoplasmic signal against MAP3K4’s reported cytosolic localisation and the selected image’s peptide-blocked comparison (HPA: approved cytosol location; A04842 caption).
What should I quantify when MAP3K4 staining varies across cell types? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, then record percentage of positive cells and staining intensity to calculate an H-score where that scale suits the study (general IHC practice). For discrete positive cells, density per mm² can be more informative; normalise counts to evaluable tissue area and exclude folds, necrosis and missing tissue (general IHC practice). Keep retrieval, detection and image exposure or scanning settings consistent, and score matched sections without changing positivity thresholds between groups (general IHC practice). Report cytoplasmic and nuclear results separately because the tissue profile describes both, whereas approved cell imaging places MAP3K4 in the cytosol (HPA: tissue profile and approved cytosol location). Include the control result and cell-type denominator with each score (general IHC practice).
When is a MAP3K4-positive section convincing rather than artefactual?
A convincing result has cellular signal in the expected cytoplasmic or perinuclear compartment and a clean matched detection control (UniProt Q9Y6R4: location; general IHC practice). Check the identity of stained cells: the tissue profile reports high staining in adrenal glandular cells and bronchial respiratory epithelial cells, but its overall reliability is uncertain (HPA: tissue profile and reliability). The selected paraffin-embedded heart image includes a peptide-blocked comparison, which supports evaluating signal specificity for that image without establishing a fixation method (A04842 caption). Treat edge-only staining, necrotic regions and signal reproduced in the no-primary control as possible artefacts, including endogenous enzyme activity with peroxidase detection (general IHC practice). Investigate predominantly nuclear signal against the approved cytosolic cell imaging location before calling it MAP3K4-specific (HPA: approved cytosol location).
Boster reagents
Best MAP3K4 / Mitogen-activated protein kinase kinase kinase 4 IHC Antibodies
A04842 has a paraffin-section human heart IHC image and is listed for IF/ICC in human and mouse samples (catalog image caption; catalog applications/reactivity).
Real IHC data
Anti-MAP3K4/Mekk4 Antibody
Cat # A04842
A04842 is the only rendered card; its IHC image shows paraffin-embedded human heart tissue with a peptide-blocked comparison (catalog image caption). It is also listed for IF and ICC in human and mouse, but no IF image is supplied (catalog applications/reactivity; catalog IF image alts).
Which to pick: Choose A04842 for paraffin-section tissue IHC when an accompanying image matters; its caption identifies paraffin-embedded human heart tissue, but does not report the fixative (catalog image caption). Choose A04842 for IF/ICC or human-and-mouse work because those applications and species are listed for this polyclonal antibody (catalog applications/reactivity; catalog dilution_raw). M04842 is a human-reactive rabbit monoclonal listed for IHC, but has no supplied IHC image or section-processing details (catalog clone/applications/reactivity; catalog IHC image alts).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9Y6R4 (M3K4_HUMAN, Mitogen-activated protein kinase kinase kinase 4).
- Human Protein Atlas. MAP3K4 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. MAP3K4 subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. MAP3K4 antibody validation summary (1 antibodies).
- Identification of MAP3K4 as a novel regulation factor of hepatic lipid metabolism in non-alcoholic fatty liver disease. Journal of translational medicine 2022 — PMC9664664.
- Her2 promotes early dissemination of breast cancer by inhibiting the p38 pathway through the downregulation of MAP3K4. Cell communication and signaling : CCS 2024 — PMC11660853.
- Hypoxic Tumor-Derived Exosomal miR-199a-3p Promote Gastric Cancer Metastasis via MAP3K4. Journal of Cancer 2023 — PMC10367928.
- Loss of mitogen-activated protein kinase kinase kinase 4 (MAP3K4) reveals a requirement for MAPK signalling in mouse sex determination. PLoS biology 2009 — PMC2733150.
- PubMed PMID:9305639 — UniProt-cited evidence.
- PubMed PMID:9039502 — UniProt-cited evidence.
- PubMed PMID:14574404 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MAP3K4 (Mitogen-activated protein kinase kinase kinase 4). Expected localisation Nuclear and cytoplasmic staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A04842 at 1:100 - 1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Skeletal muscle. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human heart tissue; fixative not specified (datasheet A04842); 2. Fixation: Image fixative and duration unreported (datasheet A04842); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-MAP3K4, 1:100 - 1:300 (datasheet A04842); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep paraffin-section fixation consistent. (standard IHC practice; not target-specific); Caveat: Skeletal myocytes show no staining despite reported high expression (HPA tissue IHC; UniProt); Isoform / epitope: 2 isoforms; epitope differences are unspecified (UniProt); Regulation: Staining intensity varies by tissue and cell type (HPA tissue IHC). Evidence: UniProt Q9Y6R4, HPA tissue IHC · Uncertain, HPA ICC-IF · cytosol., Datasheet A04842, PMC9664664. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MAP3K4/immunohistochemistry-ihc-guide.